Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10140462 | 1.00 | ITGB3 (0.34) | ITGB3ITGA2BGAACHRM1 | |
| SCHEMBL7357348 | 0.79 | GAA (0.38) | ITGB3ITGA2BGAACHRM1 | |
| SCHEMBL9387116 | 0.72 | KMT2A (0.32) | GAA | |
| SCHEMBL9835380 | 0.72 | NPC1 (0.46) | CHRM1 | |
| SCHEMBL8912860 | 0.70 | NCF1 (0.38) | CHRM1 | |
| SCHEMBL11956920 | 0.70 | PHGDH (0.43) | GAA | |
| SCHEMBL4587456 | 0.70 | PHGDH (0.43) | GAA | |
| SCHEMBL356123 | 0.70 | ITGB3 (0.30) | ITGB3ITGA2B | |
| SCHEMBL14595103 | 0.70 | ITGB3 (0.30) | ITGB3ITGA2B | |
| SCHEMBL9442983 | 0.69 | REN (0.38) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257678-A1 | VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF | INCEPT LLC (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | ITGB3 1342/4885ITGA2B 731/4885GAA 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.